Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EDITNASDAQ:FATENYSE:IKTNASDAQ:TROV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDITEditas Medicine$1.74-5.2%$1.40$0.91▼$6.22$143.99M2.152.56 million shs1.27 million shsFATEFate Therapeutics$1.24-6.4%$1.07$0.66▼$5.92$141.54M2.322.21 million shs1.33 million shsIKTInhibikase Therapeutics$2.03-2.4%$2.02$1.12▼$4.20$150.91M1.01235,333 shs67,720 shsTROVCardiff Oncology$3.41+2.1%$16.75$0.70▼$3.46$37.55M1.04648,892 shs909,012 shs10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDITEditas Medicine0.00%+11.94%+5.79%-1.98%-66.63%FATEFate Therapeutics0.00%+6.47%-5.73%+19.90%-66.44%IKTInhibikase Therapeutics0.00%+14.69%-9.78%-10.57%+10.33%TROVCardiff Oncology0.00%+12.54%+25.83%-19.58%+7.23%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEDITEditas Medicine4.3152 of 5 stars3.14.00.04.22.71.71.3FATEFate Therapeutics4.2565 of 5 stars4.12.00.04.72.11.70.6IKTInhibikase Therapeutics1.0366 of 5 stars3.30.00.00.00.60.00.6TROVCardiff OncologyN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEDITEditas Medicine 2.29Hold$5.36209.14% UpsideFATEFate Therapeutics 2.22Hold$4.14235.45% UpsideIKTInhibikase Therapeutics 2.50Moderate Buy$6.50220.20% UpsideTROVCardiff Oncology 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TROV, FATE, IKT, and EDIT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025FATEFate TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$10.00 ➝ $2.005/14/2025FATEFate TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$5.00 ➝ $4.005/14/2025FATEFate TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/13/2025EDITEditas MedicineRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$8.00 ➝ $4.004/29/2025EDITEditas MedicineCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/28/2025EDITEditas MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.004/28/2025EDITEditas MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$3.003/28/2025IKTInhibikase TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/6/2025FATEFate TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$5.00 ➝ $3.003/6/2025FATEFate TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$5.00 ➝ $4.003/6/2025FATEFate TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$5.00 ➝ $5.00(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEDITEditas Medicine$35.84M4.05N/AN/A$4.27 per share0.41FATEFate Therapeutics$13.34M10.61N/AN/A$3.74 per share0.33IKTInhibikase Therapeutics$260K580.44N/AN/A$1.78 per share1.14TROVCardiff Oncology$250K150.19N/AN/A$0.94 per share3.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEDITEditas Medicine-$153.22M-$3.04N/AN/AN/A-340.96%-80.13%-50.99%8/6/2025 (Estimated)FATEFate Therapeutics-$160.93M-$1.49N/AN/AN/A-1,325.43%-45.88%-33.95%8/12/2025 (Estimated)IKTInhibikase Therapeutics-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/ATROVCardiff Oncology-$16.41M-$2.80N/A∞N/A-3,688.31%-202.00%-122.92%N/ALatest TROV, FATE, IKT, and EDIT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025FATEFate Therapeutics-$0.39-$0.32+$0.07-$0.32$1.18 million$1.63 million5/12/2025Q1 2025EDITEditas Medicine-$0.51-$0.43+$0.08-$0.92$0.79 million$4.66 million3/5/2025Q4 2024EDITEditas Medicine-$0.39-$0.55-$0.16-$0.55$37.17 million$30.60 million3/5/2025Q4 2024FATEFate Therapeutics-$0.44-$0.31+$0.13-$0.44$1.57 million$1.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEDITEditas MedicineN/AN/AN/AN/AN/AFATEFate TherapeuticsN/AN/AN/AN/AN/AIKTInhibikase TherapeuticsN/AN/AN/AN/AN/ATROVCardiff OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEDITEditas MedicineN/A3.753.75FATEFate TherapeuticsN/A8.298.29IKTInhibikase TherapeuticsN/A0.850.85TROVCardiff Oncology0.122.372.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEDITEditas Medicine71.90%FATEFate Therapeutics97.54%IKTInhibikase Therapeutics3.81%TROVCardiff Oncology9.99%Insider OwnershipCompanyInsider OwnershipEDITEditas Medicine2.10%FATEFate Therapeutics5.51%IKTInhibikase Therapeutics7.30%TROVCardiff Oncology0.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEDITEditas Medicine23083.71 million80.98 millionOptionableFATEFate Therapeutics550114.60 million108.20 millionOptionableIKTInhibikase Therapeutics674.34 million66.18 millionNot OptionableTROVCardiff OncologyN/A11.01 millionN/ANot OptionableTROV, FATE, IKT, and EDIT HeadlinesRecent News About These CompaniesWhy Cardiff Oncology, Inc.’s (CRDF) Stock Is Up 6.08%April 29, 2025 | aaii.comCardiff Oncology announces second patent for onvansertib combinationApril 24, 2025 | markets.businessinsider.comCardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve PatientsApril 23, 2025 | tmcnet.comCardiff Oncology (NASDAQ:CRDF) Stock, Option ChainApril 23, 2025 | benzinga.comIs Cardiff Oncology, Inc. (CRDF) The Hot Biotech Stock Under $5?March 26, 2025 | insidermonkey.comCardiff Oncology’s Earnings Call: Optimism Amid ChallengesFebruary 28, 2025 | tipranks.comWilliam Blair Keeps Their Buy Rating on Cardiff Oncology (CRDF)February 27, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX) and Cardiff Oncology (CRDF)February 27, 2025 | markets.businessinsider.comWhy Cardiff Oncology, Inc.’s (CRDF) Stock Is Up 15.07%January 31, 2025 | aaii.comCardiff Oncology Inc (CRDF) Stock: More Robust Than the Numbers Suggest?December 14, 2024 | bovnews.comCardiff Oncology Inc (CRDF) Stock: Surpassing Expectations in the Market?December 14, 2024 | bovnews.comCardiff Oncology announces positive colorectal data and $40m stock oversubscriptionDecember 11, 2024 | msn.comCardiff unveils positive Phase 2 data for colorectal cancer drug, $40M offeringDecember 10, 2024 | endpts.comCardiff stock soars on onvansertib data, $40M direct offeringDecember 10, 2024 | msn.comCardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct OfferingDecember 10, 2024 | tmcnet.comStock Surge, Strong Data: Is Cardiff Oncology (CRDF) on the Brink of a Major Breakthrough?December 10, 2024 | bovnews.comCardiff Oncology Reports Positive Q3 2024 Results and Clinical ProgressNovember 9, 2024 | markets.businessinsider.comCardiff Oncology Reports Third Quarter 2024 Results and Provides Business UpdateNovember 8, 2024 | markets.businessinsider.comWhat’s Fueling Cardiff Oncology Inc (CRDF) Stock’s 7.23% Gain Above Its 200-Day SMA?November 2, 2024 | bovnews.comWhat’s Driving Cardiff Oncology Inc (CRDF) Stock’s 16.85% Surge Over the Past Month?November 1, 2024 | bovnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTROV, FATE, IKT, and EDIT Company DescriptionsEditas Medicine NASDAQ:EDIT$1.74 -0.10 (-5.19%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$1.72 -0.02 (-0.86%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Fate Therapeutics NASDAQ:FATE$1.24 -0.09 (-6.44%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$1.21 -0.03 (-2.02%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.Inhibikase Therapeutics NYSE:IKT$2.03 -0.05 (-2.40%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$2.01 -0.02 (-0.99%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.Cardiff Oncology NASDAQ:TROVCardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Apple’s Quiet HomePad Delay Could Be Its Loudest Move Yet Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
